Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders

Molecular Psychiatry volume 16, pages 691–692 (2011)Cite this article

Subjects

CYP2D6 ultrarapid metabolizers (UMs) are subjects carrying more than two active alleles, and have a much higher hydroxylation capacity. Recently, a higher frequency of CYP2D6 active genes was found among patients with eating disorders (EDs) vs healthy controls.1 Moreover, a higher frequency of UMs was found among individuals who committed suicide vs those who died from natural causes.2 Therefore, the present study analyzed the relationship between CYP2D6 genetic polymorphism and lifetime suicidal behavior in ED patients.

Risk of suicide was retrospectively analyzed in 203 women with EDs (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition) from a population previously genotyped.1 As a part of the Diagnostic Interview Schedule, participants were asked ‘Have you ever attempted suicide?’. The time frame for these questions was lifetime. A suicide attempt was defined as a self-destructive act with some degree of intent to end one's life. Thus, to be considered an attempt, the attempt was required to have two components, an action that was self-destructive and an acknowledgement of intent to die. All patients were Spanish Caucasians recruited in Bellvitge University Hospital (Barcelona, Spain). The study was performed according to the Helsinki Declaration principles. All participants gave written informed consent and corresponding approval was obtained from the institutions involved in the study.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Peñas-LLedó E, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F et al. Pharmacogenomics J; published online 28 September 2010 [e-pub ahead of print].

  2. Zackrisson AL, Lindblom B, Ahlner J . Clin Pharmacol Ther 2010; 88: 354–359.

    Article  CAS  Google Scholar 

  3. LLerena A, Dorado P, Peñas-Lledó EM . Pharmacogenomics 2009; 10: 17–28.

    Article  CAS  Google Scholar 

  4. Kawanishi C, Lundgren S, Agren H, Bertilsson L . Eur J Clin Pharmacol 2004; 59: 803–807.

    Article  CAS  Google Scholar 

  5. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A . Pharmacogenomics 2009; 10: 1111–1120.

    Article  Google Scholar 

Download references

Acknowledgements

This study was partially supported by grants from Instituto de Salud Carlos III (ISCIII)-FIS Junta de Extremadura and European Union-FEDER BS10023, PI10/02785, PI081714 and CP06/00030 (Pedro Dorado). CIBER is an initiative of ISCIII (Spain). This study was coordinated within the network Red Iberoamericana de Farmacogenética y Farmacogenómica (http://www.ribef.com).

Author information

Authors and Affiliations

  1. CICAB Clinical Research Center, Extremadura University Hospital Medical School, and CIBERSAM, Badajoz, Spain

    E M Peñas-Lledó, P Dorado & A LLerena

  2. Department of Psychiatry, University Hospital of Bellvitge-IDIBELL and Ciber Fisiopatologia Obesidad y Nutrición (CIBEROBN), Instituto Salud Carlos III, Barcelona, Spain

    Z Agüera & F Fernández-Aranda

  3. CIBER en Epidemiología y Salud Pública (CIBERESP), Genes and Disease Program, Center for Genomic Regulation (CRG-UPF), Barcelona, Spain

    M Gratacós & X Estivill

  4. Department of Clinical Sciences, University of Barcelona, Barcelona, Spain

    F Fernández-Aranda

Authors
  1. E M Peñas-Lledó
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Dorado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Z Agüera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Gratacós
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. X Estivill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F Fernández-Aranda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A LLerena
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to F Fernández-Aranda or A LLerena.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peñas-Lledó, E., Dorado, P., Agüera, Z. et al. High risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 16, 691–692 (2011). https://doi.org/10.1038/mp.2011.5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2011.5

This article is cited by

Search

Advanced search

Quick links